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Abstract
Aims/hypothesis Asymptomatic pregnant women are
screened for gestational diabetes (GDM) at 24–28 weeks’ ges-
tation. Recent guidelines also recommend screening early in
gestation to identify undiagnosed pre-existing overt diabetes.
We assessed the performance of random plasma glucose
(RPG) testing at antenatal booking in predicting GDM diag-
nosis later in pregnancy.
Methods Data from 25,543 consecutive singleton pregnancies
at the Rosie Hospital in Cambridge (UK) were obtained from
hospital electronic records as a service evaluation. All women
were invited for an antenatal RPG (12–16 weeks) and a 50 g
glucose challenge test (GCT; 24–28weeks) with a 75 g OGTT
if GCT >7.7 mmol/l (139 mg/dl).
Results At booking, 17,736 women had an RPG that was able
to predict GDM (receiver operating characteristic AUC 0.8)
according to various diagnostic criteria in common use. A cut-
off point of ≥7.5 mmol/l (135 mg/dl) gave a sensitivity of 0.70
and a specificity of 0.90 for GDM diagnosis. Theoretically,
using this screening policy, 13.2% of womenwould have been
categorised at high risk (26.3% had GDM) and 86.8% of
women at low risk (1.7% had GDM). RPG performed better
than maternal age (AUC 0.60) or BMI (AUC 0.65) at
predicting GDM diagnosis.
Conclusions/interpretation RPG at booking has reasonable
performance as a screening test and is better than maternal
age or BMI for identifying women at high risk of GDM.
RPG cannot replace OGTT for diagnosis but it may be useful
to exclude women who do not need further investigation for
GDM and to identify women who could be prioritised for
early diagnosis or lifestyle interventions.
Abbreviations
ACOG American Congress of Obstetricians and
Gynecologists
FPG Fasting plasma glucose
GDM Gestational diabetes
GCT Glucose challenge test
IADPSG International Association of the Diabetes in
Pregnancy Study Groups
LGA Large for gestational age
NICE National Institute for Health and Care Excellence
RPG Random plasma glucose
USPSTF US Preventative Services Task Force
Introduction
Gestational diabetes (GDM), defined as carbohydrate intoler-
ance causing hyperglycaemia with first onset or recognition
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during pregnancy, is associated with adverse maternal and
fetal outcomes [1, 2]. The Hyperglycaemia and Adverse Peri-
natal Outcomes (HAPO) study identified that all degrees of
hyperglycaemia are linked linearly to adverse outcomes in
pregnancy, with no obvious inflection point for this risk [3].
This has led to considerable difficulty in defining GDM. The
International Association of the Diabetes in Pregnancy Study
Groups (IADPSG) recommended setting diagnostic cut-off
points at a level consistent with an OR of 1.75 [4] (see elec-
tronic supplementary material [ESM] Table 1), which has re-
sulted in a larger number of diagnoses. These criteria have
been adopted by the WHO [5] and the ADA [6] but have
not been universally accepted [7, 8], in part due to concerns
about resource allocation with the increasing prevalence of
GDM and concerns about excessive medicalisation of healthy
pregnancy [9]. Although many countries are adopting the
WHO 2013 criteria, there remains great heterogeneity of di-
agnostic criteria used for GDM, even within the same country
[10].
There is also considerable controversy about how best to
identify women with GDM. The ADA and US Preventive
Services Task Force (USPSTF) recommend that all pregnant
women should be screened at 24–28 weeks unless they are
known to have pre-existing diabetes [6]. The American
Congress of Obstetricians and Gynecologists (ACOG) guide-
lines agree that all women should be screened at 24–28weeks’
gestation but suggest that this could be performed by assess-
ment of ‘the patient’s medical history, clinical risk factors, or
laboratory screening test results to determine blood glucose
levels’ [11]. Guidelines published by the National Institute for
Health and Care Excellence (NICE) in the UK recommend
screening only women with risk factors, including obesity,
previous GDM, family history of diabetes or ethnicity with a
high diabetes prevalence [8]. Although universal screening
policies whereby all women are screened biochemically for
GDM are considered expensive, there is some concern that
risk-factor-based approaches miss many cases who might oth-
erwise benefit from treatment [12] and create added complex-
ity for healthcare professionals conducting the screening [13].
There is also considerable controversy regarding the type
and timing of blood tests with which to diagnose GDM. The
ACOG and USPSTF recommendations from the USA have
favoured a two-step approach using a 50 g glucose challenge
test (GCT) and a confirmatory test using the 100 g OGTT
[11]. The WHO, ADA and IADPSG all recommend a one-
step approach, using a 75 g OGTTwith glucose determination
carried out at baseline and at 1 and 2 h after the glucose load.
The NICE guidelines recommend a 75 g OGTTwith glucose
measurement at baseline and at 2 h post load. Other groups
have suggested that tests such as fasting plasma glucose [14]
or random plasma glucose (RPG) [15] might have validity in
screening for GDM, either alone or as a method of rationing
OGTTs. A previous systematic review of the use of RPG to
screen for GDM concluded that there was inadequate evi-
dence to support the use of RPG, but only six relevant studies
(including a total of 3,537 women) were identified [16].
In our institution, an RPG is taken at antenatal booking
(12–16 weeks) to exclude overt diabetes [17]. Because wom-
en who develop GDM have abnormal glucose handling or
insulin resistance prior to pregnancy, we hypothesised that
the RPG may also be able to identify women who may later
develop GDM. The aim of this study was to assess the use-
fulness of an RPG taken at antenatal booking as a screening
test for GDM, diagnosed at any point during pregnancy.
Methods
Population and standard careAs described previously [18],
data from all singleton pregnancies (2004–2008) at the Rosie
Hospital, Cambridge Universities NHS Foundation Trust
were obtained retrospectively from hospital medical and ob-
stetric records as part of an approved service evaluation. At
that time in our institution, all pregnant women had been in-
vited to attend an antenatal appointment at which RPG (n=17,
736; typically 12–16 weeks’ gestation) was measured. Wom-
en with RPG >7.0 mmol/l or who had a previous diagnosis of
GDM were offered an early 75 g OGTT. All women without
known GDM/pre-existing diabetes were screened at 24–
28 weeks with a 50 g GCT: women with a GCT result
>7.7 mmol/l (139 mg/dl) were then referred for a 75 g OGTT
[18]. Additional OGTTs were performed in later pregnancy if
symptoms were present. Therefore, all women who had an
OGTT (n=3,848) had already had at least one abnormal glu-
cose test result during pregnancy, symptoms consistent with
hyperglycaemia or GDM in a previous pregnancy. Women
with known pre-existing diabetes were excluded from the
study. The study period of 2004–2008 was chosen as electron-
ic records, screening procedures and treatment protocols were
constant during this time.
Laboratory analysis Both venous and capillary blood sam-
ples were used during 2004–2008 for glucose testing in our
institution. Venous blood was collected using fluoride–oxalate
tubes and analysed using a hexokinase method (Dimension
RXL MAX Clinical Chemistry System; Siemens Healthcare
Diagnostics, Deerfield, IL, USA) in our accredited laboratory
(Clinical Pathology Accreditation, UK Accreditation Service,
Feltham, UK). Capillary samples were analysed using the
Bayer Elite glucose monitoring system (Bayer, Newbury,
UK). Although both laboratory and point-of-care methods
were regularly calibrated, small differences exist between cap-
illary and venous glucose testing [19]. The same diagnostic
criteria were used for both capillary and venous tests.
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Statistical analysis Receiver operating characteristic (ROC)
curves were used to estimate AUC and the 95% CI. Statistical
analysis was performed using STATA (version 12.0;
StataCorp, College Station, TX, USA).
Results
Records were obtained for 25,789 births; 25,543 records were
included in the analysis after exclusion of pregnancies
resulting in miscarriage (n=59) or termination (n=65) and
records with no birthweight information (n=3), duplicate
data (n=20) and data consistent with overt diabetes
(RPG ≥11.1 mmol/l at booking; n=99). Of these, only
17,736 pregnancies had a documented RPG at booking. Those
without RPG measurements recorded have been described
more thoroughly elsewhere [17].
Baseline characteristics of women are described according
to the presence or absence of GDM according to the IADPSG
criteria (Table 1). As expected, women with GDMpresent had
higher rates of obesity (BMI ≥30 kg/m2), higher age at deliv-
ery and were more likely to give birth to a macrosomic or
large-for-gestational-age (LGA) infant compared with women
who did not have GDM.
The ability of the RPG to predict GDM was tested using
ROC curves (Fig. 1). RPG was able to predict GDM accord-
ing to the IADPSG (n=1,181 positive diagnoses, n=884 with
RPG; AUC 0.81; 95% CI 0.80, 0.83), NICE 2015 (n=1,055
positive diagnoses, n=806 with RPG; AUC 0.81; 95% CI
0.79, 0.83), WHO 1999 (n=1,016 positive diagnoses;
n=775 with RPG; AUC 0.81; 95% CI 0.79, 0.83) and Mod-
ified WHO 1999 (n=1,025 positive diagnoses; n=782 with
RPG; AUC 0.80; 95% CI 0.78, 0.83) criteria.
Using a cut-off value of RPG ≥7.5 mmol/l (135 mg/dl),
which produced best overall performance of sensitivity and
specificity, RPG was able to predict GDM diagnosis using
IADPSG (sensitivity 0.70, specificity 0.90), NICE 2015
(sensitivity 0.69, specificity 0.89), WHO 1999 (sensitivity
0.69, specificity 0.89) and Modified WHO 1999 (sensitivity
0.69, specificity 0.89) criteria. In this dataset of 17,736 preg-
nancies with RPG data, 15,396 women (86.81%) fell below
this threshold and 2,340 fell above the threshold (13.19%).
As the clinical value of RPGwould be in excluding women
who do not need further investigation for GDM, a higher cut-
off value of ≥8.5 mmol/l (153 mg/dl) was also assessed to
maximise specificity while providing acceptable sensitivity.
At this level, RPG was able to predict GDM according to
IADPSG (sensitivity 0.43, specificity 0.97), NICE 2015
(sensitivity 0.42, specificity 0.96), WHO 1999 (sensitivity
0.42, specificity 0.96) and Modified WHO 1999 (sensitivity
0.42, specificity 0.96) criteria. In this dataset of 17,736 preg-
nancies with recorded RPG, 16,789 women fell below this
threshold and 947 fell above the threshold.
As the range of RPG values was considerable in women
who later developed GDM (see Fig. 1e), a cut-off point of
around ≥4.7 mmol/l (85 mg/dl) was required to give a sensi-
tivity of 90% using any diagnostic criteria. Of the 3,863 wom-
en who had values <4.7 mmol/l, 68 (1.76%) were eventually
diagnosed with GDM according to IADPSG criteria.
Theoretically, adopting an RPG screening policy in this
population using IADPSG criteria with a cut-off point of
≥7.5 mmol/l (135 mg/dl) would have identified 2,340 women
as being at high risk of GDM (Fig. 2; 615 [26.3%] were later
found to be positive for GDM). This screening policy would
also have identified 15,396 women as being at low risk of
GDM (of whom 15,127 [98.3%] were negative for GDM).
Table 1 Characteristics of all
pregnancies and those identified
as GDM-positive and GDM-neg-
ative according to the IADPSG
criteria
Characteristic All pregnancies GDM-negative
(IADPSG)
GDM-positive
(IADPSG)
No. of pregnancies 25,543 24,362 1,181
Maternal age ≥30 years at delivery 15,773 (61.8) 14,890 (61.1) 883 (74.8)
Maternal smoking at booking 2,416 (9.5) 2,342 (9.6) 74 (6.3)
Maternal white ethnicity 22,762 (89.3) 21,785 (89.6) 977 (82.8)
Maternal obesity 3,016 (13.9) 2,701 (13.1) 315 (30.0)
Primiparous 9,895 (38.8) 9,437 (38.8) 458 (38.9)
Macrosomia (BW >4 kg) 3,097 (12.1) 2,854 (11.7) 243 (20.6)
LGA (BW >90th percentile) 3,010 (12.2) 2,700 (11.5) 310 (26.9)
Method of delivery
SVD 15,321 (60.0) 14,790 (60.7) 531 (45.0)
CS 6,795 (26.6) 6,301 (25.9) 494 (41.8)
Data are shown as n (%)
Note that approximately 99.9% of records had data available for pregnancy outcome, mode of delivery and
antenatal complications but only 84.9% of records had data available for their usual maternal adult BMI
BW, birthweight; CS, Caesarean section; SVD, spontaneous vertex delivery
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However, this low-risk group contained 269 womenwhowere
confirmed positive for GDM later in pregnancy (30.4% of
cases of GDM). Interestingly, our data suggests that these
269 women might not have been readily identified using
risk-factor-based screening methods as approximately 38.7%
were of normal pre-pregnancy BMI (<25 kg/m2). They had a
33.7% risk of having an LGA infant (Fig. 2).
The use of RPG at booking compared favourably with
other screening strategies in current clinical use (Fig. 3a, b).
For example, maternal pre-pregnancy BMI and maternal age
were both inferior at predicting GDM using the IADPSG
criteria (n=1,181 positive diagnoses, n=884 with RPG; BMI
AUC 0.65, 95% CI 0.63, 0.67; age AUC 0.60, 95% CI 0.59,
0.62). Maternal age ≥30 years predicted IADPSG GDM with
a sensitivity of 74.8% and a specificity of 38.9%. Maternal
pre-pregnancy BMI ≥30 k/m2 predicted IADPSG GDM with
a sensitivity of 0.30 and a specificity of 0.87. Combining the
risk factors age and BMI with RPG did not improve the over-
all predictive ability compared with using RPG alone
(Fig. 3c–f) when using thresholds of RPG ≥7.5 mmol/l, age
≥30 years and BMI ≥30 kg/m2. However, combining age and
BMI (Fig. 3c), RPG and age (Fig. 3d) or RPG and BMI
(Fig. 3e) gave an improvement in test sensitivity to 0.83–
0.95, but at the cost of reducing the overall ROC AUC.
Discussion
This retrospective study in 17,736 pregnant women dem-
onstrates that RPG at antenatal booking has reasonable
performance as a screening test for GDM and performs
better overall than screening based upon established risk
factors (maternal age and BMI). RPG may have a role in
identifying women who are at low risk of GDM and who
would be considered to be of relatively low priority for
early diagnosis or screening. Conversely, RPG could be
used to identify women at high risk of GDM who might
benefit from earlier diagnosis or from more intensive
0
0.25
0.50
0.75
1.00
S
en
si
tiv
ity
0 0.25 0.50 0.75 1.00
1 - Specificity
0
0.25
0.50
0.75
1.00
S
en
si
tiv
ity
0 0.25 0.50 0.75 1.00
1 - Specificity
0
0.25
0.50
0.75
1.00
S
en
si
tiv
ity
0 0.25 0.50 0.75 1.00
1 - Specificity
0
0.25
0.50
0.75
1.00
S
en
si
tiv
ity
0 0.25 0.50 0.75 1.00
1 - Specificity
IADPSG
AUC 0.81
(95% CI 0.80, 0.83)
NICE
AUC 0.81
(95% CI 0.79, 0.83)
WHO-99
AUC 0.81
(95% CI 0.79, 0.83)
Mod WHO-99
AUC 0.80
(95% CI 0.78, 0.83)
a b
c d
0
500
1,000
0 5 10 0 5 10
F
re
qu
en
cy
(I
A
D
P
S
G
-n
eg
at
iv
e)
Glucose (mmol/l) 
e
500
1,000
Glucose (mmol/l)
F
re
qu
en
cy
(I
A
D
P
S
G
-p
os
iti
ve
)
f
Fig. 1 (a–d) ROC curves for the
use of RPG to predict GDM
diagnosed using the IADPSG
criteria (a), the NICE 2015
criteria (b), the WHO 1999
(WHO-99) criteria (c) and the
modified (Mod) WHO 1999
criteria (d); AUC and 95%CIs are
also shown. The distribution of
RPG values in women who were
negative (e) and positive (f) for
GDM according to the IADPSG
criteria
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GDM-positive
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30.4% GDM cases
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33.7% risk of LGA
Fig. 2 Features of women with
RPG above and below the
7.5 mmol/l (135 mg/dl) cut-off
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Fig. 3 (a, b) ROC curves
showing the use of maternal age
at delivery (a) and pre-pregnancy
BMI (b) for the prediction of
GDM using the IADPSG criteria,
as indicated in the graphs. (c–f)
Combining the predictive value of
RPG (≥7.5 mmol/l), maternal age
(≥30 years) and maternal pre-
pregnancy BMI (≥30 kg/m2)
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lifestyle interventions in early pregnancy. However, wom-
en with a low RPG still can develop GDM. This data sug-
gests that reliance on the RPG at booking alone, without
universal testing in the second trimester, would miss
around 30% of cases of GDM. The test sensitivity could
be improved by combining RPG with risk-factor informa-
tion for age or BMI, but with a reduction in the specificity
and overall ROC AUC.
This study has several strengths. First, the large sample
size and unselected nature of the population allows robust
assessment of the validity of RPG in clinical practice.
Second, the RPG measured at antenatal booking was
followed by universal screening for GDM using a two-
step GCT and 75 g OGTT protocol. However, this protocol
is no longer recommended by international guidelines
[4, 5] and, importantly, GDM has not been definitively
excluded using an OGTT in all 17,736 women. This was
a single centre study in a relatively mono-ethnic population
with a low prevalence of GDM. The overall performance of
any screening tests may vary in different populations with
different prevalence rates for GDM [16]. Over 7,000
women did not have evidence of an RPG measurement.
These women have been described elsewhere and are oth-
erwise comparable with the general population giving no
evidence of selection bias [17]. The blood was analysed in
a single accredited laboratory or using point-of-care de-
vices under established laboratory quality control proto-
cols. However, during this period both capillary and venous
testing was used for glucose quantification in our institu-
tion. This may introduce small differences between mea-
sured and actual glucose concentrations. We have no data
about the timing of OGTT testing in relation to the RPG
although most OGTTs were performed at around 28 weeks
following a GCT at 24–28 weeks. Although we have de-
tailed information on some maternal risk factors, such as
obesity and age, we do not have consistent information
about previous history of GDM or family history of type
2 diabetes.
The use of RPG has many advantages. First, it is inexpen-
sive and can be performed during the antenatal booking visit
with no special pre-test preparation. Second, the opportunity
to use point-of-care analysis on a capillary sample allows the
clinician to have prompt access to the results, facilitating early
lifestyle intervention or confirmatory testing. This may be
particularly beneficial in resource-poor or rural environments
where women travel a great distance to appointments. How-
ever, the RPG result is affected by pre-testing conditions, such
as food intake and exercise, and this gives a wide range of
RPG values in both GDM-positive and GDM-negative
populations.
Previous studies of the RPG have had conflicting results.
van Leeuwen and colleagues prospectively assessed the valid-
ity of RPG vs OGTT in 322 pregnant women and found that
the RPG at 24–28 weeks had an ROC AUC of 0.69 (95% CI
0.61, 0.78) [20]. The same authors also performed a systematic
review assessing the validity of RPG in the diagnosis of
GDM. Six papers met the entry criteria and included data
from the Netherlands [20], China [21], Japan [22], UK
[15], India [23] and Kuwait [24], with a broad range of
prevalence rates for GDM. All the studies dealt with the
performance of RPG in the second or third trimester except
for one study by Maegawa and colleagues [22] who stud-
ied 749 pregnant women in Japan (2.9% had GDM). They
found that the RPG and GCT had reasonable performance
for detecting GDM in the first trimester. Some older studies
indicated that GDM can be successfully diagnosed earlier
in pregnancy [25–27], but the validity of using the WHO
2013 criteria outside the standard 24–28 week period has
been questioned [28].
In our study, RPG with a sensitivity of 70% and specificity
of 90% compares favourably with other approaches used for
the screening of patients for GDM. A meta-analysis of the
performance of the 50 g GCT, which included 13,564 wom-
en, showed that it had a sensitivity of 0.74 (95% CI 0.62,
0.87) and a specificity of 0.85 (95% CI 0.80, 0.91) for con-
secutive patients (not just those pre-selected based on risk
factors) [29]. Other investigators have recommended a risk-
factor-based approach. Göbl and colleagues designed a risk
calculator based upon a woman’s history of previous GDM,
glycosuria, family history of diabetes, age, pre-conception
dyslipidaemia and ethnic origin [14]. The risk calculator in
addition to a fasting plasma glucose concentration was able to
predict GDM with a ROC AUC of 0.9. However, in clinical
practice, collecting detailed risk-factor information can be
challenging and prone to error and pre-conception lipid re-
sults are often unavailable. Interestingly, other reports from a
different ethnic population did not support the use of fasting
blood glucose or risk-factor-based screening. Dahanayaka
and colleagues in Sri Lanka found that fasting blood glucose
alone was a poor predictor of GDM and that a risk-factor-
based approach was only able to identify around two-thirds of
affected women [12].
This study indicates that RPG measurement could form
part of a useful testing strategy to identify women in early
pregnancy who are at risk of developing GDM, or to prioritise
second trimester OGTT testing to those most at risk of GDM.
Interestingly, although GDM is thought to develop after
20 weeks’ gestation in the majority of cases, this study shows
that women in the first trimester can already be categorised
biochemically according to their risk of later developing frank
hyperglycaemia. In healthcare systems where universal bio-
chemical screening with an OGTT is considered prohibitively
expensive, RPGmeasurement at booking is likely to be a cost-
effective and convenient way of identifying women who need
to be prioritised for early lifestyle intervention and an OGTT
in the second trimester.
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